Managing Metastatic Prostate Cancer In Your Urological Oncology Practice

Buch | Softcover

XIII, 280 Seiten

2017 | 1st ed. 2016
Springer International Publishing (Verlag)
978-3-319-52457-3 (ISBN)

Artikel merken

This text provides a comprehensive review of pathophysiology, molecular and cell biology aspects of CRPC, discusses all major clinical trials that have led to approval of 6 new drugs since 2004, explores the role of bone preservation strategies, in depth analysis of combination and sequencing strategies, outlines upcoming novel drugs and trends in research, and stresses the role of palliative care in this incurable disease. Managing Metastatic Prostate Cancer in Your Urological Oncology Practice will serve as a very useful resource for physicians and researchers dealing with, and interested in prostate cancer. It provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters are written by experts in their fields and will include the most up to date scientific and clinical information.

K.C. Balaji, MD Chief of Urology, W.G. (Bill) Hefner VA Medical Center, Salisbury, North Carolina Professor of Urology and Cancer Biology, Wake Forest University School of Medicine, Winston Salem, North Carolina Department of Urology, Cancer Biology, Institute of Regenerative Medicine Wake Forest University School of Medicine, W.G. (Bill) Hefner VA Medical Center

Introduction.- Pathophysiology of Castration-Resistant Prostate Cancer.- Androgen Receptor Signaling in Castration Resistant Prostate Cancer.- Non-Androgen Signaling Pathways in Castration-Resistant Prostate Cancer.- Predictive Models in Castration Resistant Prostate Cancer.- Docetaxel in Advanced and Castration Resistant Prostate Cancer.- Combination Treatment Strategies with Docetaxel in Patients with Metastatic Prostate.- Cancer Vaccines in Castration Resistant Prostate Cancer - An evolution in design.- Abiraterone for the treatment of mCRPC.- Enzalutamide in Metastatic Castration Resistant Prostate Cancer.- Radium-223 in Metastatic Castrate Resistant Prostate Cancer.- Cabazitaxel for the Treatment of Prostate Cancer.- Sequencing Therapies in Metastatic Castration Resistant Prostate Cancer.- Bone Preservation Strategies for Men on Androgen Deprivation Therapy.- Novel Therapies in Castration-Resistant Prostate Cancer.

Erscheinungsdatum	20.01.2017
Zusatzinfo	XIII, 280 p.
Verlagsort	Cham
Sprache	englisch
Maße	155 x 235 mm
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Urologie
Schlagworte	Abiraterone Acetate • Cabazitaxel • castration resistant prostate cancer • Docetaxol Chemotherapy • Enzalutamide • Medicine • Medicine: general issues • Oncology • Urology • Urology and urogenital medicine
ISBN-10	3-319-52457-7 / 3319524577
ISBN-13	978-3-319-52457-3 / 9783319524573
Zustand	Neuware